Clinical trial
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients…
NCT01224366 · Novartis, Industry · Completed
Key facts
| NCT number | NCT01224366 |
|---|---|
| Title | Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus |
| Official title | A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus. |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Vildagliptin, Placebo |
| Enrollment | 448 |
| Start date | Sep 1, 2010 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Oct 20, 2010 |
| Last update posted | Feb 23, 2017 |
| Countries | Australia, Belgium, Czechia, Germany, Guatemala, Hong Kong, Hungary, India, Romania, Slovakia, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: